The challenging bioamination of hydrophobic substrates has been attained through the employment of a disperse system consisting of a combination of a low polarity solvent (e. g. isooctane or methyl-tert-butylether), a non-ionic surfactant and a minimal amount of water. In these conditions, amine transaminases (ATA) were shown to efficiently carry out the reductive amination of variously substituted cyclohexanones, providing good conversions often coupled with a superior stereoselectivity if compared with the corresponding chemical reductive amination. An array of synthetically useful 4-substituted aminocyclohexanes was consequentially synthesized through biocatalysis, analyzed and stereochemically characterized. (Figure presented.)
Biocatalytic syntheses often require unfavorable conditions, which can adversely affect enzyme stabi...
The discovery and characterisation of enzymes with both monoamine and diamine transaminase activity ...
Chiral amines are important components of 40–45% of small molecule pharmaceuticals and many ot...
The challenging bioamination of hydrophobic substrates has been attained through the employment of a...
The use of enzymes, nature´s own catalysts, both isolated or as whole cells to perform chemical tran...
Compared with biocatalysis in aqueous media, the use of enzymes in neat organic solvents enables inc...
Amine transaminases are enzymes that catalyze the mild and selective formation of primary amines, wh...
Section 1 gives an overview of the importance of chiral amines, along with a short summary of import...
Amine transaminases are important biocatalysts for the synthesis of chiral primary amines. Unlike ma...
Significant progress has been made in establishing transaminases as robust biocatalysts for the gree...
As we move towards a more sustainable global economy, there is a need to develop efficient methods f...
Surfactant-enabled asymmetric ATA-catalyzed reductive aminations in aqueous buffered media are descr...
The marine transaminase, P-ω-TA, can be employed for the transamination from 1-aminotetralins and 1-...
International audienceIn the course of our research aimed at the design of new biocatalytic processe...
Many modern drugs contain chiral amine moieties and the need for more efficient processes to synthes...
Biocatalytic syntheses often require unfavorable conditions, which can adversely affect enzyme stabi...
The discovery and characterisation of enzymes with both monoamine and diamine transaminase activity ...
Chiral amines are important components of 40–45% of small molecule pharmaceuticals and many ot...
The challenging bioamination of hydrophobic substrates has been attained through the employment of a...
The use of enzymes, nature´s own catalysts, both isolated or as whole cells to perform chemical tran...
Compared with biocatalysis in aqueous media, the use of enzymes in neat organic solvents enables inc...
Amine transaminases are enzymes that catalyze the mild and selective formation of primary amines, wh...
Section 1 gives an overview of the importance of chiral amines, along with a short summary of import...
Amine transaminases are important biocatalysts for the synthesis of chiral primary amines. Unlike ma...
Significant progress has been made in establishing transaminases as robust biocatalysts for the gree...
As we move towards a more sustainable global economy, there is a need to develop efficient methods f...
Surfactant-enabled asymmetric ATA-catalyzed reductive aminations in aqueous buffered media are descr...
The marine transaminase, P-ω-TA, can be employed for the transamination from 1-aminotetralins and 1-...
International audienceIn the course of our research aimed at the design of new biocatalytic processe...
Many modern drugs contain chiral amine moieties and the need for more efficient processes to synthes...
Biocatalytic syntheses often require unfavorable conditions, which can adversely affect enzyme stabi...
The discovery and characterisation of enzymes with both monoamine and diamine transaminase activity ...
Chiral amines are important components of 40–45% of small molecule pharmaceuticals and many ot...